Yemaachi Biotech

Yemaachi Biotechnology Launches The African Cancer Atlas, in Partnership with Roche

Roche has signed as the founding partner to initiate the consortium which will generate genomic and clinical data from up to 7,500 African cancer patients ACCRA, Ghana & WASHINGTON–(BUSINESS WIRE)–Yemaachi Biotech, a pioneering genomics research company based in Ghana, announced today a partnership with Roche to launch The African Cancer Atlas (TACA). This initiative aims […]

Liquid Biopsy – The necessary first step towards democratising precision oncology?

While IHC and imaging are useful for diagnosing and staging cancers, they are limited in their ability to inform clinical decision-making regarding the use of increasingly available targeted therapies that are revolutionising cancer care in developed countries. For this, more advanced molecular tests are required, and next generation sequencing-based liquid biopsy tests are at the cutting edge.

Global team to study international differences in COVID-19 immunity

Supported by £3.1 million from the Wellcome Trust, the newly-created WWW Consortium links three leading studies in West Africa (Yemaachi Biotech Heritage Study), the West Indies (Windfall Study in Kingston, Jamaica), and West London (the Legacy Study), each tracking how both the virus and our immunity has evolved against COVID-19.